Drug Trial Radar · NCT07750704
Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC
Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
153
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Sep 2029
Study completion Mar 2030
Sponsor
- Lead sponsor
- Guangdong Association of Clinical TrialsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This investigator-initiated, open-label, prospective Phase II clinical trial, planned to take place across multiple centers in China. We design this trial to evaluate the safety and efficacy of lorlatinib plus sacituzumab tirumotecan based on peripheral blood ctDNA as first-line treatment for ALK fusion NSCLC.
Conditions
- ALK Positive Non-small Cell Lung Cancer
Interventions
LorlatinibDrug
lorlatinib 100 mg orally once daily (QD)
sacituzumab tirumotecan plus lorlatinibDrug
lorlatinib 100 mg orally once daily (QD) plus sacituzumab tirumotecan 4 mg/kg administered as an intravenous infusion on Day 1 and Day 15 of each 4-week cycle (Q4W) for 4 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1-year PFS rateTime frame: From date of first dosing to first documented progression or death from any cause, whichever came first, assessed up to 1 year.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial Perople's Hospital
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.